Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EBITDA (2018 - 2025)

10x Genomics (TXG) has disclosed EBITDA for 8 consecutive years, with -$19.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 60.79% to -$19.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$61.0 million through Dec 2025, up 68.65% year-over-year, with the annual reading at -$61.0 million for FY2025, 68.65% up from the prior year.
  • EBITDA hit -$19.5 million in Q4 2025 for 10x Genomics, up from -$32.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $30.1 million in Q2 2025 to a low of -$94.8 million in Q3 2023.
  • Historically, EBITDA has averaged -$37.3 million across 5 years, with a median of -$40.7 million in 2022.
  • Biggest five-year swings in EBITDA: crashed 471.61% in 2022 and later skyrocketed 172.18% in 2025.
  • Year by year, EBITDA stood at -$18.6 million in 2021, then decreased by 24.03% to -$23.1 million in 2022, then plummeted by 138.95% to -$55.2 million in 2023, then grew by 9.69% to -$49.8 million in 2024, then surged by 60.79% to -$19.5 million in 2025.
  • Business Quant data shows EBITDA for TXG at -$19.5 million in Q4 2025, -$32.2 million in Q3 2025, and $30.1 million in Q2 2025.